Creative Medical Technology Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.39.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.10.
During the past 3 years, the average EBIT per Share Growth Rate was 35.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 32.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
CELZ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 26.1 Med: 40.8 Max: 79.5
Current: 35
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Creative Medical Technology Holdings was 79.50% per year. The lowest was 26.10% per year. And the median was 40.80% per year.
CELZ's 3-Year EBIT Growth Rate is ranked better than 74.83% of 1172
companies
in the Biotechnology industry
Industry Median: 15.35
vs CELZ: 35.00
Creative Medical Technology Holdings (NAS:CELZ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Creative Medical Technology Holdings EBIT per Share Related Terms
Creative Medical Technology Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings (CELZ) has a EBIT per Share of $-2.10 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Creative Medical Technology Holdings and its competitors. According to the industry distribution chart, Creative Medical Technology Holdings ranks #295 out of 1172 companies in the Biotechnology industry, placing it in the top 25.2%.
Is Creative Medical Technology Holdings' EBIT per Share too high?
Creative Medical Technology Holdings' current EBIT per Share is $-2.10. Based on the distribution chart, Creative Medical Technology Holdings ranks #295 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Creative Medical Technology Holdings has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' EBIT per Share compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #295 out of 1172 companies for EBIT per Share. This puts Creative Medical Technology Holdings in the upper half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current EBIT per Share is $-2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.97 — trading 203.9% above its estimated fair value. The current EBIT per Share is $-2.10. Creative Medical Technology Holdings' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current EBIT per Share is $-2.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $0.97 is trading 203.9% above its estimated GF Value™ of $0.32.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
EBIT per Share: $-2.10
GF Value™: $0.32 vs. price of $0.97 (203.9% above fair value)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
34GF Score
Get the complete analysis for CELZ
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
